Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Annals of Clinical and Translational Neurology|April 14, 2025
ADAPT NXT: Fixed Cycles or Every-Other-Week IV Efgartigimod in Generalized Myasthenia GravisAli A Habib, Kristl G Claeys, Vera Bril, et al.
Therapeutic Advances in Neurological Disorders|September 19, 2024
Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG studyAli A Habib, Sabrina Sacconi, Giovanni Antonini, et al.
The Lancet. Neurology|January 25, 2025
Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trialAli A Habib, Chongbo Zhao, Inmaculada Aban, et al.
Neurology. Clinical Practice|July 9, 2026
Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness MethodPushpa Narayanaswami, Renato Mantegazza, Carolina Barnett-Tapia, et al.
Muscle & Nerve|May 21, 2022
Patient preference for virtual versus in-person visits in neuromuscular clinical practiceKomal Hafeez, Hani Kushlaf, Husam Al-Sultani, et al.
Neurology|May 11, 2022
Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth DiseaseFlorian P Thomas, Thomas H Brannagan, Russell J Butterfield, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 24, 2021
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating StudyStacy A Rudnicki, Jinsy A Andrews, Tina Duong, et al.
Human Mutation|February 15, 2022
Intron mutations and early transcription termination in Duchenne and Becker muscular dystrophyMegan A Waldrop, Steven A Moore, Katherine D Mathews, et al.
Lancet (London, England)|April 24, 2026
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trialTuan Vu, Ali A Habib, Saiju Jacob, et al.
Muscle & Nerve|March 2, 2026
Prospective Validation of the New PLS Diagnostic Criteria From PLS Natural History Study: EMG and Neurofilament AnalysesEric Sorenson, Daragh Heitzman, Ikjae Lee, et al.
Pageof 5